title: [Multicenter, randomized, positive-controlled clinical study for the effects of nerotropin on diabetic neuropathy].
abstract: OBJECTIVE
  To estimate the effects of Neurotropin in the treatment of neuralgia and numbness in type 2 diabetes mellitus patients with diabetic peripheral neuropathy (DPN), and compare with Methycobal.
  
  
  METHODS
  Ninety-five patients with DPN from 4 hospitals in shanghai were randomly assigned to two groups: 49 cases in Neurotropin group (6 ml, IV, QD for 2 weeks, then, 2 tablets, BID for another 2 weeks). 46 cases in Methycobal group (1 ml, IM, QD for 2 weeks, then, 1 tablet TID for another 2 weeks.
  
  
  RESULTS
  Neurotropin significantly improved neuralgia in type 2 diabetes mellitus with DPN, the efficacy rate was 67.3% in the first week, and 87.0% in the 4th week, comparing with 34.8% and 68.5% in the control group. The efficacy rate for numbness was 58.7% in the study group after 4 weeks therapy, and 69.5% in control group. In the whole 4 weeks therapeutic course, neuralgia and numbness were improved in the two groups, and the improved rate in Neurotropin group is high than in the control group (P < 0.01).
  
  
  CONCLUSIONS
  Neurotropin had good effects in the treatment of diabetic neuralgia and numbness, the efficacy of Neurotropin in improving the senses of neuralgia is better than Methecobal., and similar with Methecobal in treating numbness.
authors.affiliation: Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Rui Jin Hospital affiliated to Shanghai Second Medical University, Shanghai 200025, China. guangning@medmail.com.cn
authors.forename: Guang
authors.initials: G
authors.lastname: Ning
authors.forename: Da-jin
authors.initials: DJ
authors.lastname: Zou
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Hui-li
authors.initials: HL
authors.lastname: Xing
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Yong-ju
authors.initials: YJ
authors.lastname: Zhao
authors.forename: Jin
authors.initials: J
authors.lastname: Lu
authors.forename: Hua
authors.initials: H
authors.lastname: Xu
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
mesh_terms: D000368:Aged; D000700:Analgesics / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003929:Diabetic Neuropathies / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009437:Neuralgia / Q000188:drug therapy; D011134:Polysaccharides / Q000627:therapeutic use*
chemical_list: D000700:Analgesics; D011134:Polysaccharides; C010491:neurotropin